Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2014 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences

NOVATO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences. JMP...
February 20, 2014 07:00 ET | Source: Raptor Pharmaceutical Inc

Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial

18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine Conference Call and Webcast Today at 8:30 a.m. EST NOVATO,...
January 13, 2014 07:00 ET | Source: Raptor Pharmaceutical Inc

Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children

NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
December 10, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Submits IND for RP103 for Leigh Syndrome and Other Mitochondrial Disorders

NOVATO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and...
November 07, 2013 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Provides PROCYSBI(R) Launch Update and Third Quarter 2013 Financial Results

NOVATO, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided financial results for its third quarter and nine months ended September 30, 2013. PROCYSBI...
October 23, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceuticals and DaVita Clinical Research Launch Screening Program to Identify Patients With Late Onset Nephropathic Cystinosis

NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research® (DCR®) (NYSE:DVA) today announced a collaboration to screen blood...
October 21, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Third Quarter 2013 Financial Results Webcast and Conference Call

NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release third quarter 2013 financial results after market close on Thursday,...
September 26, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Present at Leerink Swann Rare Disease Roundtable

NOVATO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced management will present at the Leerink Swann Rare Disease Roundtable in New York on October...
September 12, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Receives Marketing Authorization for PROCYSBI(R) in European Union

NOVATO, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) has approved PROCYSBI® gastro-resistant hard...
August 29, 2013 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Announces Presentation at the International Pediatric Nephrology Association Meeting in Shanghai

NOVATO, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI (cysteamine bitartrate) will be featured in an upcoming presentation at the...